1. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE: LLY) takes the No. 1 spot among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and it is not hard to understand why Wall Street continues to treat it as one of the most powerful healthcare growth stories in the market. Trading at $1,206.51, with the stock up 6.99%, Eli Lilly and Company (NYSE: LLY) is backed by 132 hedge fund holders, making it the most widely held name in this ranking. For investors searching for healthcare stocks to buy, pharmaceutical stocks, obesity drug stocks, weight-loss drug stocks, diabetes stocks, AI-powered healthcare stocks, and long-term growth stocks, Eli Lilly and Company (NYSE: LLY) remains one of the most important companies in global medicine.
On June 23, Reuters reported that Eli Lilly and Company (NYSE: LLY) expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027. Executive Vice President Patrik Jonsson said the company plans to initially target patients paying out of pocket through telehealth partnerships. This is a major development because the weight-loss drug market has become one of the most important growth areas in the global pharmaceutical industry. Injectable GLP-1 therapies have already changed the conversation around obesity, diabetes, and metabolic health. An oral option could make treatment more convenient for some patients, potentially expanding the market further if regulatory approvals, pricing, supply, and physician adoption line up.
Jonsson told Reuters that Eli Lilly and Company (NYSE: LLY) will seek regulatory approvals before launch and plans to expand its obesity strategy through telehealth providers, e-commerce platforms, and direct-to-patient channels. That strategy is important because the way patients access weight-loss treatments is changing. Traditional physician prescriptions and public reimbursement remain important, but telehealth platforms and direct-to-patient channels have become more influential, especially for consumers willing to pay out of pocket. Eli Lilly and Company (NYSE: LLY) is applying lessons from its U.S. launch as it prepares for Europe and Britain, which suggests the company is thinking not only about the drug itself but also about distribution, consumer access, and digital health delivery.
Eli Lilly and Company (NYSE: LLY) will also continue pursuing public reimbursement where available, although uncertainty remains around President Donald Trump’s “most-favoured-nation” drug pricing policy. Jonsson said, “Our goal will still be public coverage, wherever possible,” while noting that the MFN framework “will play a role for all launches.” That issue matters because drug pricing can directly affect pharmaceutical company revenue, patient access, investor expectations, and government reimbursement decisions. Reuters reported that Eli Lilly and Company (NYSE: LLY) signed a deal with the Trump administration last year committing to provide MFN pricing for new medicines. The company also plans to pursue reimbursed prices consistent with its interpretation of the policy.
The trivia behind Eli Lilly and Company (NYSE: LLY)’s obesity drug story is that weight-loss medicine has shifted from being a niche lifestyle discussion into a massive healthcare, economic, and public policy issue. Obesity is linked to diabetes, cardiovascular disease, kidney disease, liver disease, and many other health problems, which means effective treatments could have effects far beyond cosmetic weight reduction. That is why investors are watching Eli Lilly and Company (NYSE: LLY) so closely. The company is not just selling a medicine. It is participating in one of the biggest changes in metabolic healthcare in decades. If oral weight-loss drugs become widely adopted, the addressable market could become even larger.
Eli Lilly and Company (NYSE: LLY) discovers, develops, manufactures, and sells pharmaceutical products across diabetes, oncology, immunology, neuroscience, and other therapeutic areas. For investors looking for best healthcare stocks, AI-powered healthcare stocks, pharmaceutical stocks to buy, obesity drug stocks, diabetes treatment stocks, and long-term growth stocks, Eli Lilly and Company (NYSE: LLY) stands at the top of this list because it combines strong demand, major pipeline potential, global expansion opportunities, and institutional confidence. The valuation is high, and policy risk is real, but Eli Lilly and Company (NYSE: LLY) remains one of the clearest examples of how healthcare innovation can become a major stock market growth story.
READ ALSO: Top 5 Best Biotech Stocks To Watch Now and Top 5 Biotech Stocks to Buy With Up to 215% Projected EPS Growth.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
